Last updated: March 13, 2022
Sponsor: Clinica Mediterranea
Overall Status: Completed
Phase
3
Condition
Nephropathy
Kidney Failure
Renal Failure
Treatment
N/AClinical Study ID
NCT01098032
NCTCM01
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age >=18 years
- Chronic kidney disease (estimated glomerular filtration rate <=30 ml/min/1.72 m2)and/or
- Risk score for contrast nephropathy ≥11 (according to the Mehran score; J Am CollCardiol 2004; 44: 1393-1399)
Exclusion
Exclusion Criteria:
- Pregnancy
- Heart failure (NYHA functional class III-IV)
- Acute pulmonary edema
- Acute myocardial infarction
- Recent (<=2 days) contrast media exposure
- Patients enrolled in concomitant studies
- Administration of theophylline, dopamine, mannitol and fenoldopam.
- End-stage CKD (patients on chronic dialysis)
- Systemic hypotension (systolic blood pressure < 100 mg/dl).
- Multiple myeloma
Study Design
Total Participants: 294
Study Start date:
January 01, 2009
Estimated Completion Date:
December 31, 2011
Study Description
Connect with a study center
Unversity of Ferrara, Department of Cardiology
Ferrara,
ItalySite Not Available
IRCCS Multimedica
Milan,
ItalySite Not Available
Unversity School of Medicine of Modena, Deparment of Cardiology
Modena,
ItalySite Not Available
Clinica Mediterranea
Naples, 80121
ItalySite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.